Aquatic Capital Management’s Pacira BioSciences PCRX Stock Holding History

Aquatic Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$544K	Buy	21,449 +17,704	+473%	+$418K	0.02%	767
2026 Q1	$84.6K	Buy	+3,745	New	+$83.2K	﹤0.01%	1116
2024 Q3	–	Sell	-16,500	Closed	-$472K	–	1441
2024 Q2	$472K	Sell	16,500 -6,700	-29%	-$191K	0.02%	549
2024 Q1	$678K	Buy	23,200 +17,600	+314%	+$541K	0.02%	478
2023 Q4	$189K	Buy	5,600 +700	+14%	+$20.5K	﹤0.01%	861
2023 Q3	$150K	Sell	4,900 -100	-2%	-$3.6K	0.01%	743
2023 Q2	$200K	Buy	5,000 +4,600	+1,150%	+$190K	0.01%	667
2023 Q1	$16K	Sell	400 -19,100	-98%	-$760K	﹤0.01%	1075
2022 Q4	$753K	Buy	19,500 +19,300	+9,650%	+$939K	0.06%	395
2022 Q3	$11K	Hold	200	–	–	﹤0.01%	1049
2022 Q2	$12K	Buy	+200	New	+$13.1K	﹤0.01%	939

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aquatic Capital Management's PCRX Position: Q2 2026 in Review

Aquatic Capital Management increased its Pacira BioSciences (PCRX) stake by 473% in Q2 2026, buying an estimated $418K and bringing the position to 21,449 shares worth $544K. The position accounts for 0.02% of the portfolio, ranked #767.

Aquatic Capital Management first reported a position in PCRX in Q2 2022 and has held it in 11 quarters since. The position peaked at $753K in Q4 2022. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Aquatic Capital Management held 21,449 shares of Pacira BioSciences worth $544K as of Q2 2026.
Aquatic Capital Management bought 17,704 Pacira BioSciences shares in Q2 2026, an estimated $418K.
Pacira BioSciences made up 0.02% of Aquatic Capital Management's portfolio in Q2 2026, its #767 holding.
Aquatic Capital Management first reported a position in Pacira BioSciences in Q2 2022 and has held it in 11 quarters since.
Aquatic Capital Management's Pacira BioSciences position peaked at $753K in Q4 2022.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.